Raloxifene的中國市場分析

根據統計資料，全球2億人以上的人為骨質疏鬆症所苦。若只限於中國國內的50歲女性，骨質降低或骨質疏鬆症的罹患率達到50％ (但60歲以上的女性的情況為30∼50％)。Raloxifene是治療骨質疏鬆症的非荷爾蒙劑，自1997年的上市以來，在全球各國急速普及。中國在2003年上市，2005∼2014年也以年複合成長率(CAGR) 約14％的速度擴大銷售額。

本報告提供中國的Raloxifene的市場相關分析、整體市場規模趨勢(過去5年份)和國內價格趨勢、各企業、各投藥形態的市場佔有率、主要製造商簡介、未來性的市場趨勢預測(今後5年份)等調查評估。

第1章 Raloxifene的相關概念

• 適應症
• 全球市場的銷售情形

第2章 中國的Raloxifene市場概況

• 中國的Raloxifene的專利、核准狀況
• 主要製造商
• 市場規模

第3章 中國國內的Raloxifene銷售情形的相關調查 (過去5年份)

• 銷售額
  • 整體銷售額
  • 各地區的銷售額
• 銷售量
  • 整體銷售量
  • 各地區的銷售量

第4章 中國的Raloxifene龍頭製造商的市場佔有率調查 (過去5年份)

• 市場佔有率:銷售額為基礎的
• 市場佔有率:銷售量

第5章 中國的Raloxifene的劑型的相關調查 (過去5年份)

• 各劑型的市場佔有率:銷售額為基礎的
• 各劑型的市場佔有率:銷售量為基礎的

第6章 中國國內的Raloxifene的醫院用標準價格

• Jiangsu Hengrui Medicine Co., Ltd (商標名:Bei Bang)
• Eli Lilly and Company (英國) (商標名:Evista)
• Eli Lilly and Company (西班牙) (商號 : Evista)

第7章 中國的Raloxifene的龍頭製造商 (過去5年份)

• Jiangsu Hengrui Medicine Co., Ltd
• Eli Lilly and Company

第8章 中國的Raloxifene市場未來展望 (今後5年份)

• 市場規模的預測
• 競爭情形的預測

圖表一覽

According to the statistics, over 200 million people suffer from osteoporosis in the world. Among women aged 50 and above in China, 50% have low bone mass or osteoporosis while this figure is 30%-50% among women aged 60 and above.

Raloxifene (raloxifene hydrochloride), a non-hormone drug against bone resorption, belongs to the second generation of selective estrogen receptor modulator (SERMs). Different from traditional estrogen replacement therapy (ERT) or hormone replacement therapy (HRT), raloxifene can not only prevent postmenopausal women from osteoporosis but also effectively increase bone mass and bone density so as to treat postmenopausal osteoporosis and prevent osteoporotic fracture.

When raloxifene made by Eli Lilly under the trade name of Evista entered the market in 1997, its global sales value in the first year reached up to 285 million, making it the second most successful product of Eli Lilly. However, raloxifene's annual sales value has been fluctuating around USD 1 billion after it reached its sales peak of USD 1.091 billion in 2007.

Raloxifene made by local enterprises came into the market after Evista entered China in Oct. 2003 and raloxifene's CAGR was about 14% during the period of 2005-2014 according to CRI's survey. Raloxifene enjoys a vast demand in China. Currently, raloxifene in the Chinese market are monopolized by the following three companies: Eli Lilly and Company (Spain), Eli Lilly and Company (UK) and Jiangsu Hengrui Medicine Co., Ltd, among which Eli Lilly and Company (Spain) has the largest market share of 86% for sales value in 2014.

Raloxifene market in China is expected to grow in the next few years.

Readers can get at least the following information from this report:

• market size of raloxifene in China
• competitive landscape of raloxifene in Chinese market
• price of raloxifene made by different enterprises in China
• market outlook of raloxifene in China

The author suggests the following groups of people purchase this report:

• drug manufacturers
• investors/ research institutions interested in Chinese medicine market
• any interest in the Chinese medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of Raloxifene

• 1.1. Indication
• 1.2. Sales Status in Global Market

2. Market Profile of Raloxifene in China

• 2.1. Patent and Approval Status of Raloxifene in China
• 2.2. Major Manufacturers
• 2.3. Market Size

3. Survey on Sales Status of Raloxifene in China, 2010-2014

• 3.1. Sales Value
  • 3.1.1. Overall Sales Value
  • 3.1.2. Sales Value by Regions
• 3.2. Sales Volume
  • 3.2.1. Overall Sales Volume
  • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Manufacturers of Raloxifene in China, 2010-2014

• 4.1. Market Share by Sales Value
• 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Raloxifene in China, 2010-2014

• 5.1. Share of Different Dosage Forms by Sales Value
• 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Raloxifene in Chinese Hospitals in 2014

• 6.1. Jiangsu Hengrui Medicine Co., Ltd (Trade Name: Bei Bang)
• 6.2. Eli Lilly and Company (UK) (Trade Name: Evista)
• 6.3. Eli Lilly and Company (Spain) (Trade Name: Evista)

7. Major Manufacturers of Raloxifene in Chinese Market, 2010-2014

• 7.1. Jiangsu Hengrui Medicine Co., Ltd
• 7.2. Eli Lilly and Company

8. Market Outlook of Raloxifene in China, 2015-2019

• 8.1. Forecast of Market Size
• 8.2. Forecast of Competitive Landscape

Table of Selected Charts

• Chart Approval Information of Raloxifene in China
• Chart Sales Status of Raloxifene in China
• Chart Sales Value of Raloxifene in China, 2010-2014
• Chart Sales Value of Raloxifene in Some Regions in China, 2010-2014
• Chart Sales Volume of Raloxifene in China, 2010-2014
• Chart Market Share of TOP3 Manufacturers of Raloxifene for Sales Value in China, 2010-2014
• Chart Sales Value and Market Share of Raloxifene Made by Eli Lilly (Spain) in China, 2010-2014
• Chart Sales Value and Market Share of Raloxifene Made by Jiangsu Hengrui in China, 2010-2014
• Chart Sales Value and Market Share of Raloxifene Made by Eli Lilly (UK) in China, 2010-2014
• Chart Sales Value and Market Share of Raloxifene Made by Other Manufacturers in China, 2010-2014
• Chart Price of Raloxifene Made by Jiangsu Hengrui Medicine Co., Ltd in Some Chinese Cities in 2014
• Chart Price of Raloxifene Made by Eli Lilly and Company (UK) in Some Chinese Cities in 2014
• Chart Price of Raloxifene Made by Eli Lilly and Company (Spain) in Some Chinese Cities in 2014